Chiba University Hospital

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.

  NCT07734116· Phase 1/2· Ono Pharmaceutical Co., Ltd.· Source

• Recruiting

  MSA-01 in Multiple System Atrophy

  NCT07446894· Phase 3· Tokyo University· Source

• Recruiting

  Pancreatic Cancer Screening Using the Enzeavour Assay in Japan

  NCT07605819· Cosomil, Inc.· Source

• Recruiting

  Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis

  NCT07136116· AbbVie· Source

• Recruiting

  A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

  NCT07190248· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

  NCT07015983· Phase 2· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Recruiting

  ELEVATE-HFpEF Clinical Study

  NCT06678841· Medtronic Cardiac Rhythm and Heart Failure· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Enrolling by invitation

  Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo

  NCT06831734· Novo Nordisk A/S· Source

• Recruiting

  Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy

  NCT06862596· Phase 2/3· Masahisa Katsuno· Source

• Enrolling by invitation

  ClotTriever® Thrombectomy System Use-Result Survey in Japan

  NCT06871683· Inari Medical· Source

• Recruiting

  Study to ONO-4538 in Patients With Rhabdoid Tumor

  NCT06622941· Phase 2· Ono Pharmaceutical Co., Ltd.· Source

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  NCT06623422· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

  NCT06598943· Phase 2· Eli Lilly and Company· Source

• Active, not recruiting

  A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

  NCT06568237· Phase 2· Teva Branded Pharmaceutical Products R&D LLC· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

  NCT06463587· Phase 3· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source

• Recruiting

  Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

  NCT06422143· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Japanese Coronary Intervention Using Drug Eluting and Perfusion Therapy for Left Main Disease (JDEPTH-LM Registry)

  NCT06436092· TCROSS Co., Ltd.· Source

• Recruiting

  A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  NCT06345729· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors

  NCT06390995· Phase 1/2· Takeda· Source

• Active, not recruiting

  Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT06158841· Phase 3· AbbVie· Source

• Recruiting

  Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT06297226· Phase 2· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Active, not recruiting

  Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

  NCT06253663· Phase 2· Kite, A Gilead Company· Source

• Active, not recruiting

  Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.

  NCT05930275· AbbVie· Source

• Active, not recruiting

  Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

  NCT06046222· Phase 2· NS Pharma, Inc.· Source

• Active, not recruiting

  Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

  NCT06074588· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

  NCT06041802· Phase 2· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

  NCT06045806· Phase 3· Celgene· Source

• Active, not recruiting

  Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

  NCT05822752· Phase 2· AbbVie· Source

• Active, not recruiting

  A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

  NCT05904886· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

  NCT05841537· AbbVie· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

  NCT05445778· Phase 3· AbbVie· Source

• Recruiting

  Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

  NCT05327894· Phase 3· Princess Maxima Center for Pediatric Oncology· Source

• Active, not recruiting

  A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

  NCT05476926· Hoffmann-La Roche· Source

• Active, not recruiting

  A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

  NCT05567796· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

  NCT05070858· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

  NCT04961567· Phase 3· Biogen· Source

• Active, not recruiting

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

  NCT04895358· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

  NCT04712643· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

  NCT04279847· Phase 1· Incyte Corporation· Source

• Active, not recruiting

  CHAMPION-AF Clinical Trial

  NCT04394546· Boston Scientific Corporation· Source

• Active, not recruiting

  Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

  NCT04468984· Phase 3· AbbVie· Source

Showing 50 of 58.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers4 recruiting
• Lung cancer4 recruiting
• Bronchiectasis2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Sarcoma2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Coronary artery disease1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Haemophilia1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Liver cirrhosis1 recruiting
• Multiple myeloma1 recruiting
• Multiple system atrophy1 recruiting
• Myasthenia gravis1 recruiting
• Pancreatic cancer1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease

  NCT06176365· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)

  NCT05818137· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  NCT05327114· Phase 2/3· Janssen Research & Development, LLC· Source

• Completed

  POLARx™ Cardiac Cryoablation System Post Market Clinical Study (POLAR SMART)

  NCT05282823· Boston Scientific Corporation· Source

• Recruiting

  A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

  NCT05265273· Phase 2/3· Janssen Research & Development, LLC· Source

• Completed

  Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)

  NCT05679570· Phase 2· International University of Health and Welfare· Source

• Completed

  Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

  NCT05258279· Phase 2· Juntendo University· Source

• Terminated

  A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

  NCT05322577· Phase 1/2· Amgen· Source

• Terminated

  A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis

  NCT05265728· Phase 3· Biogen· Source

• Completed

  A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)

  NCT05084053· Phase 3· Takeda· Source

• Completed

  Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

  NCT05142722· Phase 3· NewAmsterdam Pharma· Source

• Completed

  A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)

  NCT05083923· Phase 3· Biogen· Source

• Completed

  A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

  NCT05091346· Phase 1/2· Eisai Inc.· Source

• Terminated

  A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

  NCT04963270· Phase 3· Hoffmann-La Roche· Source

• Completed

  Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT05016882· Phase 2· Novo Nordisk A/S· Source

• Completed

  Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

  NCT04956692· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

  NCT04951622· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia

  NCT04813263· AbbVie· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Hoffmann-La Roche· Source

• Completed

  Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

  NCT04696055· Phase 2· Bayer· Source

• Terminated

  Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

  NCT04093362· Phase 3· Taiho Oncology, Inc.· Source

• Completed

  Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)

  NCT04624243· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

  NCT04472598· Phase 3· AbbVie· Source

• Completed

  Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

  NCT04321031· Phase 2· Pfizer· Source

• Completed

  Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ Tablets

  NCT04340115· AbbVie· Source

• Completed

  Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

  NCT05694819· Phase 2· National Cancer Center Hospital East· Source

• Completed

  A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

  NCT04102098· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus

  NCT04214028· AbbVie· Source

• Completed

  Post-marketing Surveillance (Use Result Surveillance) With Refixia®

  NCT03875547· Novo Nordisk A/S· Source

• Completed

  Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

  NCT03904693· Phase 3· Actelion· Source

• Completed

  A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

  NCT04034095· Janssen Pharmaceutical K.K.· Source

• Completed

  Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

  NCT03976375· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

  NCT03713593· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Clinical Trial of Ultra-high Dose Methylcobalamin for ALS

  NCT03548311· Phase 3· Eisai Co., Ltd.· Source

• Completed

  Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

  NCT03025308· Phase 3· Alfasigma S.p.A.· Source

• Completed

  Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III

  NCT02761070· Phase 3· Kyorin University· Source

• Completed

  Cryo Global Registry

  NCT02752737· Medtronic Cardiac Ablation Solutions· Source

• Completed

  Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

  NCT02273375· Phase 3· Canadian Cancer Trials Group· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Chronic myeloid leukaemia5 works · 0 trials
• Multiple system atrophy3 works · 2 trials